Stereotactic Ablative Radiotherapy (SAbR) for Primary Renal Cell Carcinoma

Although renal cell cancer (RCC) was demonstrated to be radioresistant for conventionally-fractionated radiation therapy (RT), mounting clinical evidence suggests that it is quite sensitive to hypofractionated RT, particularly stereotactic ablative radiotherapy (SAbR). In the setting of primary RCC, SAbR has been shown to improve control in multiple retrospective and early-phase prospective trials with favorable toxicity. In this chapter, we will review the current literature and cover the technical considerations for the setup, treatment planning, and delivery of SAbR for primary RCC.